At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 86 enrolled
Drug / intervention
Rilonacept +1 moredrug
Likely dose
Rilonacept 320 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 3, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study With Open-label Extension, to Assess the Efficacy and Safety of Rilonacept Treatment in Subjects With Recurrent Pericarditis
In Brief
A Phase 3 clinical trial evaluating Rilonacept and Placebo for Recurrent Pericarditis. Completed, enrolled 86 participants across 21 sites in 4 countries.
Detailed Summary
The primary objective of this study was to assess the efficacy of rilonacept treatment in participants with recurrent pericarditis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Pericarditis
CountriesAustralia, Israel, Italy, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartJan 2019
Primary CompletionMay 2020
Study CompletionJun 2022
TodayJul 2026
First PostedNov 9, 2018
Enrollment StartJan 7, 2019
Primary CompletionMay 29, 2020
Study CompletionJun 30, 2022
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 7.6 years ago
Interventions
Rilonaceptdrug
Rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥12 and \<18 years old) SC , followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and \<18 years old) injections once weekly
Placebodrug
Placebo SC injections once weekly